KRAS and neoplasm: However, while in theory the two sequencing tests (tumor and germline) may be ordered together for a one-time price, in clinical reality, additional tests may still be necessary, given the optimal tumor sequencing test proposed in the TSGS protocol with both MMR and prognostic biomarkers (KRAS, NRAS, and BRAF) is not yet clinically available.